协和医学杂志2025，Vol.16Issue(4)：847-854,8.DOI:10.12290/xhyxzz.2024-0577
放射性核素偶联药物:中国15年研发进程及最新政策支持
Radionuclide Drug Conjugates:China's 15-Year Research and Development Process and Latest Policy Support
摘要
Abstract
Radionuclide drug conjugates(RDC)represent the culmination of interdisciplinary integra-tion.By virtue of their precise targeting capability,high diagnostic sensitivity,and remarkable therapeutic effi-cacy in tumor diagnosis and treatment,RDC has emerged as promising theranostic agents with immense applica-tion potential.This article systematically reviews the progress in RDC development in China from 2009 to 2024,encompassing an overview of RDC,its structure and classification,trends in clinical research,advances in clinical trials,and national policy support.The aim is to provide valuable insights for researchers in related fields,thereby facilitating further development and application of RDC-based therapeutics.关键词
放射性核素偶联药物/多肽偶联核素/抗体偶联核素/靶向治疗/临床研发现状/中国在研药物Key words
radionuclide drug conjugates/peptide-radionuclide conjugates/antibody-radionuclide conjugates/radionuc-lide targeted therapy/status of clinical research and development/drugs under development in China分类
医药卫生引用本文复制引用
刘丹,李修齐,刘书鹏,吴晓霏,余孟洋,王洪允..放射性核素偶联药物:中国15年研发进程及最新政策支持[J].协和医学杂志,2025,16(4):847-854,8.基金项目
首都卫生发展科研专项(2022-2Z-4018) （2022-2Z-4018）
中央高水平医院临床科研专项(2022-PUMCH-B-118) Capital's Funds for Health Improvement and Research(2022-2Z-4018) （2022-PUMCH-B-118）
National High Level Hospital Clinical Re-search Funding(2022-PUMCH-B-118) （2022-PUMCH-B-118）
